BRPI0514416A - formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade - Google Patents

formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade

Info

Publication number
BRPI0514416A
BRPI0514416A BRPI0514416-7A BRPI0514416A BRPI0514416A BR PI0514416 A BRPI0514416 A BR PI0514416A BR PI0514416 A BRPI0514416 A BR PI0514416A BR PI0514416 A BRPI0514416 A BR PI0514416A
Authority
BR
Brazil
Prior art keywords
controlled release
release
dosage forms
low solubility
solubility drug
Prior art date
Application number
BRPI0514416-7A
Other languages
English (en)
Inventor
Leah Elizabeth Appel
Dwayne Thomas Friesen
Scott Max Herbig
Avinash Govind Thombre
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0514416A publication Critical patent/BRPI0514416A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMAS DE DOSAGEM DE LIBERAçãO CONTROLADA COMBINANDO LIBERAçãO IMEDIATA E LIBERAçãO CONTROLADA DE UM FáRMACO DE BAIXA SOLUBILIDADE Uma forma de dosagem de liberação controlada compreende uma porção de liberação imediata e um núcleo de liberação controlada de revestimento entérico.
BRPI0514416-7A 2004-08-31 2005-08-19 formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade BRPI0514416A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60595504P 2004-08-31 2004-08-31
PCT/IB2005/002825 WO2006024949A2 (en) 2004-08-31 2005-08-19 Controlled release dosage forms combining immediate release and sustained release of low-solubility drug

Publications (1)

Publication Number Publication Date
BRPI0514416A true BRPI0514416A (pt) 2008-06-10

Family

ID=35746910

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514416-7A BRPI0514416A (pt) 2004-08-31 2005-08-19 formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade

Country Status (6)

Country Link
EP (1) EP1789022A2 (pt)
JP (1) JP2008511609A (pt)
BR (1) BRPI0514416A (pt)
CA (1) CA2578474A1 (pt)
MX (1) MX2007002375A (pt)
WO (1) WO2006024949A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
JP5527921B2 (ja) * 2006-12-22 2014-06-25 エスエス製薬株式会社 苦味を隠蔽した経口固形組成物
UA113858C2 (uk) 2011-10-21 2017-03-27 Такеда Фармасьютікал Компані Лімітед Лікарський засіб піоглітазону з уповільненим вивільненням
WO2014171542A1 (ja) * 2013-04-19 2014-10-23 武田薬品工業株式会社 放出制御製剤
RU2018111400A (ru) * 2015-09-01 2019-10-03 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Препарат пролонгированного, отсроченного и немедленного высвобождения, способ его получения и применения
WO2019014273A1 (en) 2017-07-10 2019-01-17 Gel Cap Technologies, LLC DOSABLE DOUBLE-DOSED CAPSULE FOR RELEASE AND METHODS, DEVICES AND SYSTEMS FOR PRODUCING THE SAME
GB201719769D0 (en) * 2017-11-28 2018-01-10 Cronin 3D Ltd Analytical device and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
DE60039802D1 (de) * 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
JP2007504266A (ja) * 2003-09-02 2007-03-01 ファイザー・プロダクツ・インク ジプラシドンの持続放出剤形

Also Published As

Publication number Publication date
CA2578474A1 (en) 2006-03-09
WO2006024949A3 (en) 2006-05-04
JP2008511609A (ja) 2008-04-17
WO2006024949A2 (en) 2006-03-09
MX2007002375A (es) 2007-04-23
EP1789022A2 (en) 2007-05-30

Similar Documents

Publication Publication Date Title
BRPI0514416A (pt) formas de dosagem de liberação controlada combinando liberação imediata e liberação controlada de um fármaco de baixa solubilidade
CR20140274A (es) Formulaciones de pepticuerpos terapéuticos liofilizados
AR059194A1 (es) Formas de dosificacion resistentes a la manipulacion
DE602007000323D1 (de) Abgabe von therapeutischen Vorrichtungen
FR2883179B1 (fr) Comprime enrobe
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
DK2018158T3 (da) Ny racecadotril administrationsform
IL180883A0 (en) Dosage forms with an enterically coated core tablet
MX2007002898A (es) Tableta con liberacion gastrointestinal controlada en sitio y tiempo del ingrediente activo.
RS54158B1 (en) AMILOID BINDING AGENTS
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
NO20072285L (no) S-mirtazapin for behandling av hetetokter
CY2016019I2 (el) Θεραπευτικη αγωγη της σκληρυνσης κατα πλακας (ms) me campath-1h
BRPI0913297A2 (pt) composição, farmacêutica, uso de uma composição, e, kit terapêutico.
NO20073023L (no) Forhindring av vertikal endoparasitt infeksjoner
CL2008003259A1 (es) Compuestos derivados de amida heterociclica; agente de control de fitoenfermedades que comprende a dichos compuestos; metodo de control de fitoenfermedades; y su uso de dichos compuestos.
EA200600066A1 (ru) Тамсулозинсодержащее ядро, покрытое поливинилпирролидоном или поливинилацетатом
WO2007077454A3 (en) A therapeutic composition comprising an inhibitor of an hsp 90 protein
ATE479428T1 (de) Olanzapin enthaltende pharmazeutische zusammensetzung
IS7537A (is) Notkun á nýjum etónógestrel esterum.
CL2012000350A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl.
WO2012028922A3 (en) Controlled release pharmaceutical compositions of milnacipran
FR2873757B1 (fr) Tuyere convergente de turboreacteur
DE202004019778U1 (de) Dübel
ATE543508T1 (de) Therapeutische verwendung von gba2

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE.